Publicaciones en colaboración con investigadores/as de Complejo Hospitalario de Toledo (32)

2024

  1. Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)

    Scientific Reports

2022

  1. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

    Scientific Reports, Vol. 12, Núm. 1

2021

  1. A dataset for the analysis of antibody response to glycan alpha-Gal in individuals with immune-mediated disorders

    F1000Research, Vol. 9

  2. Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: Costecat Study

    International journal of environmental research and public health, Vol. 18, Núm. 2

2020

  1. Clinical validation of risk scoring systems to predict risk of delayed bleeding after EMR of large colorectal lesions

    Gastrointestinal Endoscopy, Vol. 91, Núm. 4, pp. 868-878.e3

  2. First national survey of the diagnosis of Helicobacter pylori infection in Clinical Microbiology Laboratories in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 9, pp. 410-416

2019

  1. Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: Phase III clinical trial

    BMJ Open Ophthalmology, Vol. 4, Núm. 1

2018

  1. Clinical guidelines for endoscopic mucosal resection of non-pedunculated colorectal lesions

    Gastroenterologia y Hepatologia

  2. Consensus SEO-SEFH of recommendations for use and compounding of ophthalmic preparations

    Farmacia Hospitalaria, Vol. 42, Núm. 2, pp. 82-88

  3. Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

    Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098

  4. Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 36, Núm. 3, pp. 194-195

2017

  1. Development of a risk stratification model for pharmaceutical care in HIV patients

    Farmacia Hospitalaria, Vol. 41, Núm. 3, pp. 346-356

2016

  1. Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain

    Journal of Infection, Vol. 72, Núm. 2, pp. 152-160

  2. Coste de la psoriasis y artritis psoriásica en cinco países de Europa: una revisión sistemática

    Actas Dermo-Sifiliograficas, Vol. 107, Núm. 7, pp. 577-590

2015

  1. "Big data"; application and use for the health system

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

  2. Methods to obtain platelet-rich plasma and osteoinductive therapeutic use

    Farmacia Hospitalaria, Vol. 39, Núm. 3, pp. 130-136

  3. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: Variation between label dosage and real-world use

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 15, Núm. 5, pp. 851-858

2013

  1. Integral oncology patient information system (OncoBASS): 5-year assessment

    European Journal of Oncology Pharmacy, Vol. 7, Núm. 1, pp. 10-14

2011

  1. Malaria hidden in a patient with diffuse large-B-cell lymphoma and sickle-cell trait

    Journal of Clinical Microbiology, Vol. 49, Núm. 12, pp. 4401-4404

2010

  1. Cumplimiento y percepción del consentimiento informado en la reproducción asistida

    Atencion Farmaceutica, Vol. 12, Núm. 3, pp. 162-171